Zhong Hui, Shen Jian-Ying, Liao Xiao-Yun, Sheng Xing-Ting, Huang Xiao-Xue, Tan Deng-Yu, Fu Lin-Lin, Fan Yu
Department of Hematology, Chongqing University Three Gorges Hospital, Chongqing, China.
Psychiatry Clin Psychopharmacol. 2024 Dec 17;34(4):336-341. doi: 10.5152/pcp.2024.24947.
This study was designed to determine the effects of acceptance and commitment care in the treatment of aplastic anemia (AA) patients with recombinant human thrombopoietin (rhTPO).
The clinical records of 100 AA patients treated at our hospital from March 2021 to March 2023 were analyzed in the retrospective study. All patients received immunosuppressants and rhTPO. Among them, 46 patients who received routine care from March 2021 to March 2022 were allocated to the control group, and the other 54 patients who received acceptance and commitment care from April 2022 to March 2023 were assigned to the study group. The quality of life (QoL) of the 2 groups was assessed by the MOS 36-Item Short-Form Health Survey (SF-36) before care and after 3 months of care. Blood-related indicators after care were compared in 2 groups.
Before care, no significant inter-group discrepancy was observed in SF-36 scores in all dimensions (P > .05); whereas after nursing, the SF-36 scores of both groups increased conspicuously in all dimensions (P < .001), especially the study group (P < .001). After care, no significant differences were observed in hemoglobin (Hb), platelet count (PLT), and white blood cell count (WBC) between the 2 groups (P > .05). A conspicuously lower overall response rate was observed in the control group in contrast to the study group (P = .044), and no significant inter-group discrepancy was found in the total incidence of adverse reactions (P = .506).
Acceptance and commitment care is conducive to the patients with AA treated by rhTPO, because it substantially improves the QoL of patients, without increasing adverse reactions, so it is worth promoting.
本研究旨在确定接受与承诺疗法在重组人血小板生成素（rhTPO）治疗再生障碍性贫血（AA）患者中的效果。
在这项回顾性研究中，分析了2021年3月至2023年3月在我院接受治疗的100例AA患者的临床记录。所有患者均接受免疫抑制剂和rhTPO治疗。其中，2021年3月至2022年3月接受常规护理的46例患者被分配到对照组，2022年4月至2023年3月接受接受与承诺疗法护理的54例患者被分配到研究组。在护理前和护理3个月后，通过医学结局研究36项简短健康调查（SF-36）评估两组患者的生活质量（QoL）。比较两组护理后的血液相关指标。
护理前，两组在SF-36各维度评分上均未观察到显著的组间差异（P>.05）；而护理后，两组在所有维度上的SF-36评分均显著提高（P<.001），尤其是研究组（P<.001）。护理后，两组之间的血红蛋白（Hb）、血小板计数（PLT）和白细胞计数（WBC）无显著差异（P>.05）。与研究组相比，对照组的总体缓解率明显较低（P = .044），且两组在不良反应总发生率上未发现显著的组间差异（P = .506）。
接受与承诺疗法有利于rhTPO治疗的AA患者，因为它能显著提高患者的生活质量，且不增加不良反应，因此值得推广。
